CRL
stock Healthcare Diagnostics & ResearchOverall Concerning · 23%
- Fundamentals Weak
- Trajectory Steady
- Leadership Churning
A read across fundamentals, recent price & growth trajectory, and leadership stability. For fun and reading at a glance, not investment advice.
What the indicators say
Mixed 4 of 5 trend signals bullishRSI 58 — firm momentum, not yet overbought.
A mechanical reading of the chart’s indicators — not investment advice.
Key statsas of Jun 3
- Open
- $179.93
- +2.94%
- Close
- $179.93
- +2.94%
- Current
- $179.93
- Prev close
- $174.79
- Today
- 439.09K
- 3-mo avg
- 874.16K
Earningscalendar synced from Yahoo 57d ago
- Most recent
- May 775 days ago
- Next expected
- Aug 5in 15 days
Recent earnings dates
- May 7 75 days ago
- Feb 18 153 days ago
- Jan 13 189 days ago
- Nov 5, 2025 258 days ago
Past earnings dates come from CRL’s 8-K item 2.02 filings; the next date is Yahoo’s when available, otherwise estimated from the recent reporting cadence.
Fundamentalssynced from SEC 51d ago
Across the nine graded ratios (FY2025 balance-sheet figures, P/E on TTM through Mar 2026 earnings, against the latest price), CRL’s fundamentals read as weak overall.
Earnings per share were negative, so a P/E cannot be formed; the company was unprofitable over the period.
Share price divided by earnings per share: what you pay for each $1 of yearly profit. Roughly 15 to 25 is typical, above 40 is richly priced, and negative means the company is losing money.
This company pays no dividend, common for firms reinvesting their profits back into growth.
The yearly dividend as a percent of the share price: the cash income each share pays out. Around 2 to 6% is healthy; above roughly 8% often signals the payout may be cut.
A -3.6% margin is thin; little of each revenue dollar survives as profit.
The share of revenue left as profit once every cost is paid. Above 15% is strong; below 5% leaves little cushion against a bad year.
A -4.6% return on equity is weak; owners' capital is barely being put to work.
Profit earned on each dollar of shareholder equity: how well the company compounds its owners' capital. Above 15% is strong.
A -2.0% return on assets is low; the asset base is generating little profit.
Profit earned on each dollar of assets: how efficiently the whole asset base is used. Above 8% is strong.
At 1.24, the company carries a moderate, manageable amount of debt.
Total liabilities divided by shareholder equity: how heavily the company leans on borrowing. Below 1 is conservative; above 2 is highly leveraged.
At 1.29, short-term assets cover short-term bills with a little room to spare.
Current assets divided by current liabilities: whether short-term resources cover short-term bills. Above 1.5 is comfortable; below 1 is tight.
Revenue fell 0.9% from the prior year; the top line is contracting.
Change in annual revenue from the prior fiscal year: whether the top line is expanding. Above 10% is strong growth; below 0 means revenue is shrinking.
Profit swung to a loss from a profitable prior year.
Change in annual net income from the prior fiscal year: whether profit is expanding. Above 10% is strong; below 0 means profit is falling.
Financialssynced from SEC 51d ago
| FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|---|
| Revenue | $3.5B | $4.0B | $4.1B | $4.0B | $4.0B |
| Net income | $391.0M | $486.2M | $474.6M | $22.2M | -$144.3M |
| Diluted EPS | $7.60 | $9.48 | $9.22 | $0.20 | $-2.91 |
| Dividend / share | — | — | — | — | — |
| Total assets | $7.0B | $7.6B | $8.2B | $7.5B | $7.1B |
| Total liabilities | $4.4B | $4.6B | $4.5B | $4.0B | $3.9B |
| Shareholder equity | $2.5B | $3.0B | $3.6B | $3.5B | $3.2B |
| Q2-2024 | Q3-2024 | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 | Q4-2025 | Q1-2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.0B | $1.0B | $1.0B | $984.2M | $1.0B | $1.0B | $994.2M | $995.8M |
| Net income | $94.1M | $69.7M | -$214.5M | $25.5M | $52.3M | $54.4M | -$276.6M | -$14.8M |
| Diluted EPS | $1.74 | $1.33 | $-4.17 | $0.50 | $1.06 | $1.10 | $-5.57 | $-0.30 |
| Dividend / share | — | — | — | — | — | — | — | — |
Leadershipsynced from SEC 57d ago
- Andrews Nancy C Director
- Barg Steven Director
- Ceesay Abraham Director
- Enyedy Mark J Director
- Graves Paul W Director
- Kemps-Polanco Reshema Director
- Llado George Sr. Director
- Mackay Martin Director
- Thompson Craig B. Director
Officers and board are drawn from CRL’s recent SEC ownership filings (Forms 3, 4 and 5).
Notable recent eventspast year
- May 28 +10.2% one-day move
- May 15 New 6-month low (-33% off peak)
- May 11 Officer or director change reported in an 8-K
- May 5 +7.6% one-day move
- Apr 23 −9.2% one-day move
- Mar 31 +8.0% one-day move
- Mar 12 −9.6% one-day move
- Mar 10 −5.4% one-day move
- Feb 18 Officer or director change reported in an 8-K
- Feb 11 −8.4% one-day move
- Feb 5 −8.9% one-day move
- Feb 3 −5.5% one-day move
- Jan 9 Officer or director change reported in an 8-K
- Dec 27, 2025 FY2025 net income −750% YoY
- Dec 3, 2025 +5.7% one-day move
- Nov 5, 2025 −5.7% one-day move
- Oct 1, 2025 +9.0% one-day move
- Sep 30, 2025 +6.4% one-day move
- Sep 19, 2025 Officer or director change reported in an 8-K
- Sep 16, 2025 Officer or director change reported in an 8-K
Large daily moves, new 6-month lows, year-over-year fundamentals swings, and reported leadership changes — pulled from the data this app already holds, never investment advice.
Recent SEC filingssynced from SEC 51d ago
- 8-K Current report
- 10-Q Quarterly report
- 8-K Current report
- DEF 14A Proxy statement
- 8-K Current report
- 10-K Annual report
- 8-K Current report
- 8-K Current report
- 8-K Current report
- 8-K Current report
- 8-K Current report
- 8-K Current report
- 10-Q Quarterly report
- 8-K Current report
- 8-K/A Current report (amended)
- 8-K Current report
- 10-Q Quarterly report
- 8-K Current report